Neurogene Inc NGNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $23.93
- Day Range
- $23.93–24.35
- 52-Week Range
- $16.21–43.54
- Bid/Ask
- $24.14 / $24.63
- Shares Outstanding
- 20.70M
- Market Cap
- $501.17M
- Volume/Avg
- 8,131 / 301,377
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 131
- Website
- https://www.neurogene.com
Valuation
Metric | NGNE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.40 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NGNE |
|---|---|
Quick Ratio | 19.82 |
Current Ratio | 19.97 |
Interest Coverage | −64,698.00 |
Quick Ratio
NGNE
Profitability
Metric | NGNE |
|---|---|
Return on Assets (Normalized) | −33.92% |
Return on Equity (Normalized) | −37.00% |
Return on Invested Capital (Normalized) | −39.39% |
Return on Assets
NGNE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&B>%gv> | LOCK|Mgm<? | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|cd#xH! | LOCK|Nn>Z | $99B | |||
| Moderna Inc MRNA | LOCK|@#&<$w | LOCK|D!D | $90B | |||
| argenx SE ADR ARGX | LOCK|^@v!!N& | LOCK|Qq | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|x&lH&mp | LOCK|SqS | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|F%cxJ?gf | LOCK|z!tJ | $31B | |||
| Incyte Corp INCY | LOCK|QkG%Jn | LOCK|$K | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|fn&V^? | LOCK|#y&% | $22B | |||
| BioNTech SE ADR BNTX | LOCK|g>%n!Q | LOCK|wKc | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&?^cwsD | LOCK|rQ | $16B |